Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American Society of Clinical Oncology
2025-07-01
|
| Series: | JCO Global Oncology |
| Online Access: | https://ascopubs.org/doi/10.1200/GO-25-00216 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849422671263039488 |
|---|---|
| author | Kumar Prabhash Roshan Pawar Vijaya Gunjal |
| author_facet | Kumar Prabhash Roshan Pawar Vijaya Gunjal |
| author_sort | Kumar Prabhash |
| collection | DOAJ |
| format | Article |
| id | doaj-art-31e22c1c2f0a4d0d8ed9642a468fd15e |
| institution | Kabale University |
| issn | 2687-8941 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | American Society of Clinical Oncology |
| record_format | Article |
| series | JCO Global Oncology |
| spelling | doaj-art-31e22c1c2f0a4d0d8ed9642a468fd15e2025-08-20T03:30:57ZengAmerican Society of Clinical OncologyJCO Global Oncology2687-89412025-07-011110.1200/GO-25-00216Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck CancerKumar Prabhash0Roshan Pawar1Vijaya Gunjal2Kumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, IndiaKumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, IndiaKumar Prabhash, MD, DM, Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India; Roshan Pawar, MD, Medical Department, Alkem Laboratories Limited, Mumbai, India; and Vijaya Gunjal, MD, DM, Medical Department, Alkem Laboratories Limited, Mumbai, Indiahttps://ascopubs.org/doi/10.1200/GO-25-00216 |
| spellingShingle | Kumar Prabhash Roshan Pawar Vijaya Gunjal Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer JCO Global Oncology |
| title | Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer |
| title_full | Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer |
| title_fullStr | Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer |
| title_full_unstemmed | Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer |
| title_short | Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer |
| title_sort | reply to critical review efficacy and safety of biosimilar cetuximab versus innovator cetuximab in indian patients with head and neck cancer |
| url | https://ascopubs.org/doi/10.1200/GO-25-00216 |
| work_keys_str_mv | AT kumarprabhash replytocriticalreviewefficacyandsafetyofbiosimilarcetuximabversusinnovatorcetuximabinindianpatientswithheadandneckcancer AT roshanpawar replytocriticalreviewefficacyandsafetyofbiosimilarcetuximabversusinnovatorcetuximabinindianpatientswithheadandneckcancer AT vijayagunjal replytocriticalreviewefficacyandsafetyofbiosimilarcetuximabversusinnovatorcetuximabinindianpatientswithheadandneckcancer |